Gen-Probe Begins U.S. Clinical Study Of PROGENSA PCA3 Assay, New Molecular Test To Help Assess Prostate Cancer Risk

Gen-Probe Incorporated announced that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy. "Based on the results of our extensive clinical research studies and our European commercial experience, we believe that our PROGENSA PCA3 assay can help predict the risk of a positive follow-up biopsy, thereby improving patient care," said Eric Lai, PhD, Gen-Probe's senior vice president of research and development. "In addition, this is an important step forward in our efforts to maximize the economic value of our oncology strategy." The clinical study of the PROGENSA PCA3 assay is expected to conclude i...